由内源凝血途径继发生成的凝血酶 (FⅡa)可活化一个被称之为凝血酶活化的纤溶抑制物 (TAFI) ,该物质具有下调纤溶系统活性、防止血凝块被纤溶酶 (PL)过早溶解的作用 ,从而使止血栓更加稳固。通过干扰内源凝血途径的关键环节 ,不但可使血凝块形成的体积变小 ,而且可使其对PL的敏感性增强 ,从而为血栓性疾病的治疗提供新思路。 Thrombin (FIIa), secondary to the intrinsic coagulation pathway, activates a fibrinolytic inhibitor known as thrombin activator (TAFI), which has the ability to down-regulate fibrinolytic system activity and prevent blood clots from being released by plasmin (PL) premature dissolution of the role, so that more stable hemostatic bolt. By interfering with the key steps of the endogenous coagulation pathway, not only the volume of the formation of blood clots can be reduced, but also the sensitivity to PL can be enhanced, thus providing new ideas for the treatment of thrombotic diseases.